本文選題：卵巢支持-間質(zhì)細(xì)胞瘤 + 免疫組化��； 參考：《山東大學(xué)》2014年碩士論文

【摘要】：目的 近幾年來(lái),免疫組織化學(xué)技術(shù)發(fā)展迅速且應(yīng)用普遍,免疫組化指標(biāo)對(duì)腫瘤診斷具有高度的敏感性和特異性,在臨床上對(duì)腫瘤的診斷、鑒別診斷、評(píng)估、分期、治療、及預(yù)后有著重要的指導(dǎo)意義和應(yīng)用價(jià)值。本次實(shí)驗(yàn)研究通過(guò)免疫組織化學(xué)技術(shù)分析CK、Vimentin、ER、PR、CD9、Inhibin-α、Calretinin等7種免疫組化指標(biāo)在卵巢支持-間質(zhì)細(xì)胞瘤與卵巢子宮內(nèi)膜樣腺癌中的表達(dá),對(duì)其不同表達(dá)率進(jìn)行統(tǒng)計(jì)學(xué)處理,明確這些免疫組化指標(biāo)在兩種不同腫瘤診斷中的應(yīng)用價(jià)值及鑒別診斷意義。 方法 選取我院病理科2008年1月～2011年12月常規(guī)石蠟切片病理診斷為Sertoli-Leydig細(xì)胞瘤的石蠟標(biāo)本44例為實(shí)驗(yàn)組,選取2008年1月～2011年12月常規(guī)石蠟切片病理診斷為卵巢子宮內(nèi)膜樣腺癌的石蠟標(biāo)本44例為對(duì)照組,進(jìn)行常規(guī)石蠟制片,用CK、Vimentin、ER、PR、CD99、Inhibin-α、Calretinin進(jìn)行免疫組化染色,然后對(duì)免疫組化染色結(jié)果進(jìn)行鏡下觀察,記錄染色結(jié)果,統(tǒng)計(jì)這些不同指標(biāo)表達(dá)的陽(yáng)性率,運(yùn)用統(tǒng)計(jì)學(xué)方法對(duì)這七種免疫組化指標(biāo)在卵巢支持-間質(zhì)細(xì)胞瘤和卵巢子宮內(nèi)膜樣腺癌細(xì)胞中的不同表達(dá)率進(jìn)行處理分析,并對(duì)常見(jiàn)的與Sertoli-Leydig細(xì)胞瘤容易在形態(tài)學(xué)上相互混淆的卵巢內(nèi)膜樣腺癌的相同免疫組化指標(biāo)的表達(dá)情況進(jìn)行對(duì)比,明確這些免疫指標(biāo)在兩種不同腫瘤診斷及鑒別診斷中的意義。 結(jié)果 CK、Vimentin、ER、PR、CD99、Inhibin-α、Calretinin等7種免疫組化指標(biāo)是免疫組織化學(xué)中常用的標(biāo)記物,從組織細(xì)胞水平進(jìn)行抗原抗體反應(yīng),標(biāo)記抗體和顯色劑特殊顯色來(lái)確定組織細(xì)胞內(nèi)的抗原(蛋白質(zhì)及多肽),對(duì)其進(jìn)行定位、定性及定量,敏感性高,定位準(zhǔn)確,臨床應(yīng)用意義極大。在本實(shí)驗(yàn)研究中,免疫組化指標(biāo)CK、ER、PR、Inhibin-α、Calretinin及CD99在卵巢支持-間質(zhì)細(xì)胞瘤和卵巢子宮內(nèi)膜樣腺癌細(xì)胞兩種不同腫瘤細(xì)胞中的表達(dá)率差異具有顯而易見(jiàn)的統(tǒng)計(jì)學(xué)意義,而Vimentin在以上兩種腫瘤細(xì)胞中的表達(dá)率差異無(wú)明顯統(tǒng)計(jì)學(xué)意義,換句話說(shuō),在應(yīng)用免疫組化鑒定兩種細(xì)胞的來(lái)源上Calretinin、CD99、 CK、Inhibin-α、ER及PR可以作為一組免疫指標(biāo),在兩種不同腫瘤的診斷及鑒別診斷中具有舉足輕重的意義。 結(jié)論 免疫組化指標(biāo)Calretinin、CD99、CK、Inhibin-α、ER、PR在卵巢支持-間質(zhì)細(xì)胞瘤和卵巢子宮內(nèi)膜樣腺癌的表達(dá)率差異有明顯的統(tǒng)計(jì)學(xué)意義,在這兩種不同腫瘤的診斷及鑒別診斷中具有重要意義和臨床應(yīng)用價(jià)值；而Vimentin在以上兩種腫瘤細(xì)胞中的表達(dá)率差異無(wú)明顯統(tǒng)計(jì)學(xué)意義,即此種免疫組化指標(biāo)在卵巢支持-間質(zhì)細(xì)胞瘤和卵巢子宮內(nèi)膜樣腺癌的鑒別診斷中意義不大。
[Abstract]:Purpose In recent years, the immunohistochemical technique has developed rapidly and is widely used. The immunohistochemical index has a high sensitivity and specificity to the diagnosis of tumor, the diagnosis, differential diagnosis, evaluation, staging and treatment of tumor in clinic. And prognosis has important guiding significance and application value. In this study, immunohistochemical technique was used to analyze the expression of seven immunohistochemical indexes, including CKP Vimentinerian PRT CD9, Inhibin- 偽 and Calretinin, in ovarian Sertoli stromal cell tumor and endometrioid adenocarcinoma of ovary, and the different expression rates were analyzed statistically. To determine the value of these immunohistochemical markers in the diagnosis of two different tumors and the significance of differential diagnosis. Method From January 2008 to December 2011, 44 paraffin wax specimens diagnosed as Sertoli-Leydig cell tumor by routine paraffin section in our department of pathology were selected as experimental group. From January 2008 to December 2011, 44 paraffin specimens of ovarian endometrioid adenocarcinoma diagnosed as ovarian endometrioid adenocarcinoma by pathology from January 2008 to December 2011 were selected as control group. The specimens were prepared by routine paraffin wax, and the immunohistochemical staining was performed with CK Vimentin ERP CD99 / Inhibin- 偽 Calretinin. Then the immunohistochemical staining results were observed under microscope, the staining results were recorded, and the positive rates of the expression of these different indicators were counted. The different expression rates of these seven immunohistochemical markers in ovarian Sertoli stromal cell tumor and ovarian endometrial adenocarcinoma were analyzed by statistical method. The expression of the same immunocytochemical markers in ovarian endometrioid adenocarcinoma, which is easily confused in morphology with Sertoli-Leydig cell tumor, was compared, and the significance of these immunological markers in the diagnosis and differential diagnosis of two different tumors was determined. Result Seven immunocytochemical markers, such as CKVimentinerian, CD99, Inhibin- 偽 and Calretinin, are commonly used as markers in immunohistochemistry, and the antigen-antibody reaction is carried out at the histocyte level. To determine the antigen (protein and polypeptide) in tissue cells by special coloration of antibody and chromogenic agent, the localization, qualitative and quantitative analysis, high sensitivity, accurate location and great clinical application significance. In this study, the expression rates of CD99 and CD99 in ovarian Sertoli stromal cell tumor and ovarian endometrial adenocarcinoma cell line were significantly different, and the difference was statistically significant in the expression of CKERERP / Inhibin- 偽 Calretinin and CD99 in ovarian Sertoli stromal cell tumor and ovarian endometrial adenocarcinoma cell line. But there was no significant difference in the expression rate of Vimentin between the two kinds of tumor cells. In other words, Calretinin CD99, CKP Inhibin- 偽 ER and PR could be used as a group of immunological markers in identifying the origin of the two kinds of cells by immunohistochemistry. It plays an important role in the diagnosis and differential diagnosis of two different tumors. Conclusion The expression rate of CKInhibin- 偽 ERPR in ovarian Sertoli Leydig cell tumor and endometrioid adenocarcinoma was significantly different from that of Calretininus CD99, and had important significance and clinical application value in the diagnosis and differential diagnosis of these two kinds of tumors. However, there was no significant difference in the expression rate of Vimentin between the above two types of tumor cells, that is, this immunohistochemical index was of little significance in the differential diagnosis of ovarian Sertoli stromal cell tumor and ovarian endometrioid adenocarcinoma.
【學(xué)位授予單位】：山東大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類(lèi)號(hào)】：R737.31

【參考文獻(xiàn)】

相關(guān)期刊論文 前9條

1 朱進(jìn);金先慶;;Bcl-2、鈣視網(wǎng)膜蛋白在發(fā)育異常腸壁神經(jīng)節(jié)細(xì)胞中的表達(dá)[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2010年01期

2 李先茂,李燕,趙彤,朱梅剛,張進(jìn)華;霍奇金淋巴瘤CD99基因表達(dá)缺失的意義[J];第四軍醫(yī)大學(xué)學(xué)報(bào);2004年23期

3 韓守威,曹澤毅,何斌,王靖華,陳曼玲;人體正常卵巢和卵巢腫瘤中雌激素及孕激素受體的研究[J];華西醫(yī)科大學(xué)學(xué)報(bào);1989年03期

4 張曄,糜若然;卵巢上皮性腫瘤雌激素受體、孕激素受體測(cè)定的臨床意義[J];天津醫(yī)藥;2000年08期

5 范Z湘，

本文編號(hào)：1859957